Halofuginone Analog Design for Reduced Toxicity and Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis, inflammatory diseases, and autoimmune disorders often involve compounds like halofuginone, which have toxicity issues and limited potency, necessitating the development of less toxic and more potent analogs with broader therapeutic applications.
Innovation Solution
Development of novel quinazolinone, quinolinone, and heteroaryl derivatives of halofuginone that inhibit metazoan and non-metazoan tRNA synthetases, specifically targeting glutamyl-prolyl tRNA synthetase (EPRS) to suppress fibrotic behavior, inflammatory responses, and autoimmune differentiation, while offering improved toxicity profiles and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If halofuginone and its derivatives are used to inhibit tRNA synthetases for treating fibrosis and inflammatory diseases, then therapeutic efficacy is improved, but toxicity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of halofuginone through variations in substituents at different positions (R1-R6 groups, halogen atoms, alkyl chains) to optimize the balance between therapeutic efficacy and toxicity. This involves changing physical and chemical parameters of the molecule to achieve desired biological activity while reducing adverse effects
Solution Approach 2:
The patent applies local quality by introducing different substituent groups at specific positions of the quinazolinone core structure. Each position (R1, R2, R3, R4, R5, R6) can be independently modified with specific functional groups to enhance target selectivity and reduce off-target toxicity, thereby improving the therapeutic index
2Reliability
If halofuginone analogs are developed to enhance potency against EPRS, then inhibition effectiveness is improved, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into a core quinazolinone structure and separate substituent groups (R1-R6). This modular approach allows systematic optimization of each segment to enhance EPRS inhibition while maintaining overall structural manageability and facilitating structure-activity relationship analysis
Solution Approach 2:
The patent applies universality by designing a core quinazolinone structure that serves multiple functions: maintaining structural stability, providing binding affinity to EPRS, and allowing versatile substitution patterns. This multi-functional core enables the development of a series of analogs with varying potencies while sharing a common scaffold
Data Source
AI summary
The present invention provides novel analogs and derivatives of halofuginone. The invention also provides pharmaceutical and cosmetic compositions thereof and methods for using halofuginone analogs in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, ischemic damage, transplant and implant rejection, neurodegenerative diseases, and cosmetic applications.